Whether scientific advice should be sought before the next trial from phase-3

Situation

Phase-3 protocol with endpoint-sensitivity issues arrived with an FAERS cluster in a demographic the trials under-enrolled for RWE evidence-strategy director. That is a Pharma & Life Sciences FDA Response and Labeling decision on scientific advice should be in a 505(b)(2) program relying on literature plus a bridging study.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• The population in phase-3 protocol with endpoint-sensitivity issues is the one an FAERS cluster in a demographic the trials under-enrolled named, so Proceed under protocol follows for this FDA Response and Labeling file.
• The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to an FAERS cluster in a demographic the trials under-enrolled; Pause the pathway is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained an FAERS cluster in a demographic the trials under-enrolled before phase-3 protocol with endpoint-sensitivity issues arrived; no new FDA Response and Labeling path.
• Provenance on phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled.
• For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move scientific advice should be for RWE evidence-strategy director.

Recommendation